Ignite Creation Date:
2024-05-05 @ 9:39 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00932893
Status:
COMPLETED
Last Update Posted:
2017-01-02
First Post:
2009-06-30
Brief Title:
An Investigational Drug PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase ALK Gene
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Randomized Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy Pemetrexed Or Docetaxel In Patients With Advanced Non-small Cell Lung Cancer Nsclc Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase Alk Gene Locus
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-012595-27 | EUDRACT_NUMBER | None | None |